Introduction {#s1}
============

A fundamental challenge of disease surveillance systems is how to transform data that is routinely collected into useful, actionable evidence that can inform control interventions. Disease surveillance systems typically focus on analyzing aggregate counts of cases over defined time periods to stratify the risk of populations ([@bib42]). However, the use of raw case counts, or incidences, as a measure of disease risk can frequently be misleading because the quality of surveillance often differs significantly both across countries and within regions of a country making comparisons inappropriate. Areas with more complete reporting of disease may inaccurately appear to have more disease simply because reported cases scale linearly with completeness of reporting. Surveillance systems may change over time (e.g. improving in completeness over time) making comparisons difficult or even impossible. These problems are particularly troubling when examining disease trends or ranking regions according to their disease risk. Recent efforts have tried to improve quantification of disease burden by pooling numerous sources of data. For example, disease mapping methods that combine disease presence/absence data, environmental covariates and available incidence data (from cohort or cross-sectional studies) have been used to predict spatial limits and global case counts for diseases including malaria, dengue and several neglected tropical diseases. ([@bib13]; [@bib2]; [@bib29]; [@bib14]) However, while these methods are successful in identifying boundaries of endemic areas, the robustness of these approaches to quantify transmission within endemic areas has not been validated.

For most immunizing infections (infections that generate long-lasting sterilizing immunity), serological surveys are regarded as the gold standard to measure the susceptible fraction and infer the extent of transmission, as they provide a direct measure of the proportion of the population that has been infected. This is particularly useful for diseases such as dengue, influenza or Zika, where the asymptomatic to symptomatic ratios are large or unknown. Methods to estimate transmission parameters from age-stratified serological data have been available for many years([@bib27]) and have been used to analyze trends in transmission for multiple diseases including measles ([@bib11]), hepatitis A([@bib35]), dengue ([@bib9]; [@bib17]; [@bib30]; [@bib31]), pertussis ([@bib23]), influenza ([@bib25]), malaria ([@bib3]) and chikungunya ([@bib34]). While well conducted age-stratified serological surveys can provide an unbiased measure of the susceptibility profile of a population and transmission parameters, they are generally not part of routine surveillance activities and are therefore only available for a limited number of locations and time points. For example, an extensive review of the dengue literature published recently found only three population-based serosurveys conducted in Brazil over the past 10 years, despite being the country that currently reports the largest number of cases worldwide ([@bib10]). Similarly, only one and three studies were identified for the Philippines and Thailand, respectively, even though the burden of dengue is very high ([@bib10]). Thus, the picture provided by serology is very incomplete and limited when trying to characterize transmission across time and space both within and between countries.

While aggregated case counts can be misleading when quantifying disease risk, the age distribution of incident cases contains a lot of information on the age-specific susceptibility of the population. Importantly, the age distributionof cases is also largely robust to under-reporting, facilitating the comparison between locations or over time. By combining age-specific incidence data and mechanistic models of how population immunity is acquired over time, it is possible to estimate key transmission parameters and obtain a much more accurate picture of the local and global burdens of disease. Since age-specific counts are routinely collected by surveillance systems as part of standard practice, they represent a missed opportunity to further our understanding of epidemic patterns for many diseases.

Here, we use dengue virus as an example to illustrate how age-specific incidence data can be used to quantify disease transmission and inform control interventions. Dengue is a relevant example because, despite being the most widely spread mosquito-transmitted virus, large gaps remain in our understanding of its global and local epidemiology ([@bib10]). We present a model to estimate the transmission intensity of dengue from age-specific incidence data, and apply it to surveillance data from administrative units in four countries that suffer from endemic dengue transmission (Thailand, Colombia, Brazil and Mexico). We validate our estimates using serological data and show that they correlate well with known environmental drivers of dengue transmission at subnational level. Finally, we show how this approach could be used to guide the implementation of dengue control strategies such as vaccination.

Results {#s2}
=======

We estimated the average forces of infection (FOI) over the last 20 years for 148 administrative level one units where age specific case data was available ([Table 1](#table1){ref-type="table"}, [Figure 1B](#fig1){ref-type="fig"}): 72/76 provinces of Thailand, 28/32 departments of Colombia, 21/27 states of Brazil, and 27/31 states of Mexico. These administrative units comprise 90%, 99%, 90% and 91% of the population at risk of these countries respectively. We also estimated forces of infection for 211 municipalities (administrative level two units) of Colombia where at least 200 cases were reported over the period covered by the data.

![Estimating FOI from age-specific incidence data in Thailand, Colombia, Brazil and Mexico.\
(**A**) Examples of the age-specific incidence of dengue observed in two settings with very high endemic transmission (Thailand 1- Udon Thani, Thailand; Brazil 1 Pernambuco, Brazil) and two settings with lower and very low transmission (Thailand 2 = Chiang Mai, Thailand; Brazil 2 = Parana, Brazil). (**B**) Maps of our estimates of the FOI for the four countries. (**C**) Correlation between our estimates of the force of infection, with estimates derived from age-stratified serological data (gold standard) for 16 settings where we had both types of data (Thailand: Rayong ([@bib31]); Bangkok ([@bib17]); Ratchaburi ([@bib17]); Lop Buri, Narathiwat, Trang, Ayuttayah ([@bib41]). Brazil: Pernambuco ([@bib30]); Salvador ([@bib44]). Colombia (unpublished). Mexico: Morelos ([@bib1]), Yucatan ([@bib15]). The locations of the specific cities are shown in the maps in panel B.](elife-45474-fig1){#fig1}

The average FOI (the rate at which susceptible individuals that will become infected in a year by any dengue serotype) was 0.096 in Thailand (95%CI 0.092-0.100), 0.132 (95%CI 0.128-0.136) in Colombia, 0.124 (95%CI 0.116-0.128) in Brazil, and 0.052 (95%CI 0.048-0.056) in Mexico. This implies that on average 9.6% of the susceptible population in Thailand gets infected every year by any of the circulating serotypes ($1 - e^{- FOI}$). Similarly, 12% of the susceptible population of Colombia and Brazil, and 5% of the susceptible population of Mexico get infected yearly.

However, as expected, transmission intensity varied greatly within countries, ranging between 0.04 and 0.15 (coefficient of variation (CV) = 0.27) across provinces of Thailand; between 0.02 and 0.20 across departments of Colombia (CV = 0.37), between 0.02 and 0.24 across states of Brazil (CV = 0.56); and between 0.01 and 0.092 across states of Mexico (CV = 0.45). Transmission was highest in the North East of Brazil (average FOI of 0.152) and in the Caribbean region of Colombia (average FOI of 0.156). There was also substantial heterogeneity within departments of Colombia. The mean CV for 15 departments where we had estimates for more than 5 municipalities was 0.4.

For the 16 locations where we had access to both age-stratified serological data (the gold standard) and case data, we found good correlation between the estimates of the FOI derived from both data sources (R2 = 0.73, 95% CI 0.51--0.87, [Figure 1C](#fig1){ref-type="fig"}). In contrast, we found no correlation between recent incidence of dengue in these locations (the average yearly incidence over the most recent 5 years of data) and the estimates of FOI derived from serological data (R2 = 0.002, [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}).

Since estimates of transmission intensity derived from seroprevalence data are only available for a small number of locations, to further validate our method we also explored the association between our estimates of the FOI for 211 Colombian municipalities (administrative level 2) with known environmental drivers of dengue transmission including temperature, elevation, precipitation a published metric of *Aedes aegypti* abundance and population density ([Figure 2](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Models were weighted by the number of cases used to estimate the FOI. On average, the FOI increased by 0.006 (95% CI 0.004--0.007, R^2^ = 0.19) for each additional °C in temperature and, similarly, it decreased by 0.005 (95% CI 0.003, 0.006, R^2^ = 0.21) for each 100 m increase in elevation ([Table 2](#table2){ref-type="table"}). While population density was not associated with FOI estimates in unadjusted analyses, a twofold increase in density was associated with a 0.007 (95% 0.004--0.009) increase in FOI in the best fitting adjusted model. This model included elevation, population density and precipitation, and explained 35% (95%CI 23--50%) of the variance.

![Correlation between estimates of the FOI and known environmental drivers of dengue transmission.\
Top panels show correlation between estimates of the FOI for 211 municipalities (administrative level 2) of Colombia and mean temperature (**A**), elevation (**B**) and Aedes abundance (**C**). Size of symbols is proportional to the number of cases available to estimate the FOI. Bottom panels shows lack of correlation between environmental drivers and recent incidence, the most commonly used metric of transmission intensity. R^2^ values reported were obtained by fitting weighted linear regression models, with weights proportional to the number of cases used to derive the FOI estimate.](elife-45474-fig2){#fig2}

In contrast, the recent incidence of dengue in these municipalities was not correlated with temperature, elevation or *Aedes aegypti* abundance (R2 0.01, 0.01, and 0.00 respectively, [Table 3](#table3){ref-type="table"}). We did find a negative association between population density and incidence, indicating a 6% (95%CI 2--10%) decrease in log incidence for each 2-fold increase in population density.

Application: Guiding dengue vaccination policy {#s2-1}
----------------------------------------------

The only available dengue vaccine (Dengvaxia) has been licensed for use in children 9 years or older in 20 countries including Thailand, Brazil and Mexico. The WHO currently recommends confirmation (by virology or serology) of prior dengue infection at the individual level before vaccinating individuals, and therefore there is interest in identifying populations with high seropositivity to target pre-vaccination screening ([@bib43]). In the absence of appropriate rapid serological assays that would allow implementing this individual screening strategy, an alternative that has been discussed is rolling out the vaccine in settings with 80% or greater seropositivity among 9 year olds. Using our estimates of the FOI, we calculated the proportion of the population expected to be seropositive at age 9 years for each of the subnational units represented in our data. Our results suggest that only a small minority of locations in Colombia and Brazil have \> 80% seropositivity in this age group ([Figure 3](#fig3){ref-type="fig"}, [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}). The expected proportion seropositive at 9 years of age ranged between 0.35 and 0.75 in provinces of Thailand; 0.13 and 0.85 in departments of Colombia; 0 and 0.88 in states of Brazil; and 0.07 and 0.56 in states of Mexico. The seroprevalence was estimated to be high enough in only 2/28 Colombian departments, 4/25 Brazilian states and none of the 72 Thai provinces or 27 Mexican states. Furthermore, even within the two Colombian departments that met the 80% seroprevalence threshold, only 9/13 (70%) of the municipalities evaluated reached this level. This proportion would probably be much lower had we considered all the municipalities in these departments, as those excluded had, on average, lower FOI ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}).

![Guiding vaccination policy.\
Estimated dengue seroprevalence at 9 years of for administrative level 1 units of Thailand, Colombia, Brazil and Mexico Expected seroprevalence of dengue among children aged 9 years, derived from the FOI estimates (see Materials and methods for more details), for administrative level 1 units of Thailand (**A**), Colombia (**B**), Brazil (**C**) and Mexico (**D**). For each country, administrative units were ranked by their FOI. Dashed lines indicate 50% and 80% seroprevalence levels. Therefore, units above the 80% line are those where, according to the WHO-SAGE recommendation from 2018, it might be reasonable target children aged 9 years old for vaccination. Units below the 50% line are those where vaccination of this age-group would not be recommended. The axis on the right of the plot indicates the minimum age-group that would need to be targeted in each location to ensure at least 80% seropositivity.\
10.7554/eLife.45474.009Figure 3---source data 1.Estimated forces of infection and seroprevalences for 148 spatial units.](elife-45474-fig3){#fig3}

In locations where seroprevalence among 9 year olds was estimated to be less than 80%, we calculated the age-group that could be targeted to ensure a seroprevalence \> 80%. Our results suggest that, to comply with the WHO-SAGE recommendations, it would be necessary to target children 14 years of age or older in over 70% (108/148) of locations. Furthermore, in approximately 50% of the locations evaluated, it would be necessary to target individuals aged 18 years or older, precluding school-based vaccination strategies.

Alternative metrics {#s2-2}
-------------------

Both the incidence and the mean adjusted incidence performed very poorly in ranking spatial units compared to the FOI ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). In contrast, the proportion of incidence under 10 years and the mean age of cases (to a lesser degree) performed quite well at ranking spatial units within countries. However, none of these metrics performed as well as the FOI when comparing spatial units from different countries, and they did not correlate as well with the gold standard (FOI estimates derived from seroprevalence data) ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}).

Sensitivity analyses {#s2-3}
--------------------

Since different surveillance systems have different reporting practices, we compared FOI estimates obtained when using data from severe cases alone (DHF or severe dengue) to estimates obtained when all dengue cases were considered jointly ([Figure 4](#fig4){ref-type="fig"}). This comparison was limited to Colombia, Brazil and Mexico because we only had DHF data from Thailand.

![Sensitivity analysis: Comparing different types of data.\
(**A**) Correlation between estimates of the FOI obtained when using data from DHF/severe dengue infections, vs. data from all cases combined. (**B**) Correlation between FOI estimates derived from different types of dengue data, with estimates derived from age-stratified serological data (gold standard).](elife-45474-fig4){#fig4}

In general, estimates derived from all cases tended to underestimate those obtained from DHF cases, but the correlation between the estimates was good ([Figure 4A](#fig4){ref-type="fig"}) as well as the correlation with the gold standard ([Figure 4B](#fig4){ref-type="fig"}). The correlation was highest for Colombia and Mexico (r = 0.74 and r = 0.78, respectively), but less so for Brazil (r = 0.48). However, 2/3 of the Brazilian locations that showed discrepant results had the smallest number of DHF cases (n = 217 and 265) suggesting that sample size may have played a role. Similarly, all the Colombian locations where there was a large discrepancy had very low counts of DHF cases (n = 41, 55, and 48, respectively).

Discussion {#s3}
==========

In this paper, we use dengue virus as an example to illustrate how age-specific incidence data can be used to quantify disease transmission and inform control interventions. We present a method to estimate the FOI of dengue from age-specific incidence data, and use it to generate country-wide subnational estimates for Thailand, Colombia, Brazil and Mexico. Our estimates correlate well with those derived from seroprevalence data (the gold standard), capture the expected spatial heterogeneity in risk, and outperform all other metrics traditionally used by surveillance systems, such as the crude incidence.

Most surveillance systems use crude case counts or incidences to describe temporal and spatial trends of communicable diseases. Our results underscore the extent to which, for immunizing infections in endemic circulation, recent incidence may be a poor metric of transmission and may be misleading when ranking spatial units ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Immunity of the population in high-transmission settings reduces the number of individuals that are susceptible to infection. As a result, incidence in places where transmission intensity is lower, but people remain susceptible for a longer period of time, may be roughly equivalent to that in higher transmission intensity areas. In contrast, metrics such as the FOI, that quantify the risk among the susceptible population, better reflect the underlying transmission potential. Since FOI estimates are derived from the age distribution of incidence, and not from the aggregate counts, they are more robust to differences in surveillance efficiency and can be obtained with relatively small numbers of yearly cases.

Our estimates of the average transmission intensity of dengue in Thailand, Colombia, Brazil and Mexico are consistent with large variation in dengue transmission between and within countries. Spatial heterogeneity was substantial not only between, but also within administrative level one units. While this heterogeneity is probably driven by multiple environmental, socio-economic and demographic factors, our results suggest that as much as 35% of the variance may be explained by differences in temperature/elevation and population density alone. Transmission intensity was highest in northeastern Brazil, northern Colombia and eastern Thailand. Northeastern Brazil was also the region that experienced the highest incidence of Zika during the 2015/2016 epidemic, and this is not surprising given that both viruses are transmitted by the same mosquito vector (*A. aegypti*)([@bib24]).

While age-stratified serological data remains the gold standard to quantify dengue transmission, our results illustrate how inferences derived from age-specific surveillance data could be used to inform control interventions such as vaccination. For example, the high transmission intensities (and expected seroprevalences) found in Northeastern Brazil suggest that this region might be ideal to implement pre-vaccination screening strategies. In addition, the large heterogeneity estimated in Colombia suggests that decisions of where to deploy control interventions, including vaccines, should be made at least at the municipal/district (administrative level 2) level. Since age-specific counts are routinely collected by many surveillance systems, they represent a unique opportunity to further our understanding of dengue burden and risk at spatial scales at which serological data is rarely available. While here we focus on presenting average forces of infection over 20 years, the same methods can also be used to estimate yearly forces of infection ([@bib16]; [@bib6]).

There are several limitations of using age-specific surveillance data to estimate transmission parameters of dengue. Of concern are differences in case definitions and reporting practices between and within countries. While the case-definition of DHF is quite specific, milder forms of the disease are characterized by a non-specific febrile syndrome. Therefore, data from locations that report 'all cases' rather than more severe forms (DHF) are more likely to be misclassified, and could be less useful to infer transmission histories. Nevertheless, our results and sensitivity analyses are encouraging and suggest that that even data from all dengue cases can be useful to infer transmission patterns.

Our model also makes several assumptions that may be questionable. It assumes that the age distribution of cases represents the age distribution of secondary infections, thus ignoring the potential contribution of primary, tertiary and quaternary infections. It also assumes that risk of infection, symptoms, and health seeking behavior are not age dependent, even though there is some evidence that suggests that this may not be the case([@bib22]; [@bib12]; [@bib39]). It assumes equal circulation of all serotypes, despite the known dominance of specific serotypes for extended periods of time in the Americas ([@bib22]; [@bib38]). Finally, it estimates transmission intensities over extended periods of time (20 years), averaging over variations in the FOI that may occur at shorter time scales. Despite these simplifications, validation of our estimates using age-stratified serological data from 16 locations is very encouraging, as is the good correlation with known drivers of dengue transmission. While further validation is desirable, it is important to note that some discrepancy between our estimates and those derived from seroprevalence data is expected as the two sources of data do not represent exactly the same period of time and location. For example, most of the serosurveys available were conducted in specific urban centers, while case data represents the full administrative unit.

Targeting control interventions against dengue and other communicable diseases requires good understanding of when and where transmission is occurring. Careful analyses of age-specific incidence data can provide very useful information to characterize transmission across time and space. While here we focus on dengue, the same approach should be generalizable to other immunizing infections including chikungunya and Zika. Open access to age-specific incidence data would greatly enrich and enhance existing efforts to quantify trends in the global burden of disease.

Materials and methods {#s4}
=====================

Data used {#s4-1}
---------

We used data on the yearly age-specific reported number of dengue cases for administrative level 1 units of Thailand, Colombia, Brazil and Mexico ([@bib26]; [@bib4]; [@bib8]; [@bib21]) as well as administrative level two units from Colombia. The period of time available varied between countries, but ranged between 5 years in Colombia and 25 years in Thailand. Where possible (Thailand and Brazil) we used age-specific case reports on dengue hemorrhagic fever (DHF) for our analyses. However, for both Colombia and Mexico, we had to use data on all reported dengue cases because the number of DHF cases reported by a substantial number of spatial units (9/32 units in Colombia and 10/31 in mexico) were insufficient to estimate the FOI. We also used population data from each administrative unit analyzed, available from the national statistical office of each country. Information on the type (e.g. DHF vs. all dengue), source and years of data used are provided in [Table 1](#table1){ref-type="table"}.

10.7554/eLife.45474.011

###### Data sources used

  Country    Years of data available   Type of report available   Type of report used   No. admin units analyzed\*   Source of dengue data   **Source of census data**
  ---------- ------------------------- -------------------------- --------------------- ---------------------------- ----------------------- ---------------------------
  Thailand   1985--2010                DHF                        DHF                   72                           ([@bib4])               ([@bib28])
  Colombia   2007--2012                DHF/DF                     All cases             28/211                       ([@bib21])              ([@bib7])
  Brazil     1998--2015                DHF/DF†                    DHF                   21                           ([@bib26])              ([@bib19])
  Mexico     2000--2009                DHF/DF                     All cases             27                           ([@bib8])               ([@bib20])

\*Admin level one/Admin level two units with at least 150 cases reported.

†Data from Brazil is on hospitalized dengue fever and dengue hemorrhagic fever cases.

10.7554/eLife.45474.012

###### Association between environmental variables and dengue force of infection for 211 municipalities in Colombia

  Variable                    Unadjusted   Adjusted                   
  --------------------------- ------------ ---------------- --------- ------------------
  Elevation (per 100 m)       −0.005       −0.003,--0.006   −0.007    −0.008,--0.006
  Mean temperature (per °C)   0.006        0.004, 0.007               
  Mean weekly precipitation   0.0001       −0.000, 0.001    −0.0005   −0.0008, −0.0002
  Population density          −0.001       −0.003, 0.001    0.007     0.004, 0.009

10.7554/eLife.45474.013

###### Association between environmental variables and the log incidence of dengue (over the last 5 years) for 211 municipalities in Colombia.

  Variable                        Unadjusted   Adjusted\*              
  ------------------------------- ------------ -------------- -------- --------------
  Elevation (per 100 m)           −0.02        −0.03, 0       0.01     −0.01, 0.03
  Mean temperature (per °C)       0.01         0, 0.05                 
  Mean weekly precipitation       0            0, 0           −0.002   −0.01, 0
  Population density              −0.04        −0.07,--0.01   −0.06    −0.10, −0.02
  \* R2 of adjusted model: 0.04                                        

Statistical analyses {#s4-2}
--------------------

### Estimating the force of infection {#s4-2-1}

We estimated the average force of infection (FOI, λ) of dengue, over the last 20 years, for each administrative unit for which we had available data. The FOI is a metric used to characterize the transmission intensity in a specific setting and estimates the per capita rate at which susceptible individuals are infected. Methods to estimate transmission intensity from age-specific incidence data have been previously used to reconstruct the transmission history of measles and dengue ([@bib11]; [@bib6]). Briefly, these methods rely on the fact that, for immunizing infections, accumulation of immunity shapes the age distribution of future cases. In settings with high endemic transmission, incident cases are expected to be concentrated in younger age groups, as adults are likely to be already immune ([Figure 1A](#fig1){ref-type="fig"}). In contrast, in places where there is less population immunity, the age distribution of cases is more likely to resemble the age distribution of the population itself, with cases in in both children and adult populations.

Methods to estimate dengue forces of infection from case data have been applied to settings where dengue is thought to be close to endemic circulation ([@bib6]; [@bib18]). These methods generally rely on the cumulative incidence proportion, and therefore assume that all individuals are infected by dengue at some point in their lifetime. They also often assume that the distribution of cases (of dengue hemorrhagic fever cases in particular) is representative of the distribution of secondary cases. Here, we extend these methods to accommodate settings where transmission hazards are lower or where dengue may have been more recently introduced. We do this by modeling directly the age-specific incidence of cases, rather than the cumulative incidence proportion.

The fraction of the population susceptible to all dengue serotypes at age a and t, x(a,t) is given by,$$x\left( {a,t} \right) = e^{\int_{0}^{a} - 4\lambda{({t - \tau})}d\tau}.$$where λ(t) is the average FOI per serotype at time t and 4λ(t) is the total FOI assuming four circulating serotypes. The proportion of individuals of age a who have been infected with only serotype at time t, but are still susceptible to all other serotypes is denoted z1(a,t) and is given by:$$z_{1}\left( {a,t} \right) = 4\left( e^{- \int_{0}^{a}3\lambda{({t - \tau})}d\tau} \right)\left( {1 - e^{- \int_{0}^{a}\lambda{({t - \tau})}d\tau}} \right).$$

Assuming that the age-specific incidence of cases is representative of the distribution of secondary infections, the expected incidence rate among individuals age a at time t is given by$$I\left( {a,t} \right) = 3\lambda\left( t \right)z_{1}\left( {a,t} \right)$$and the expected reported number of cases is$$\left( {a,t} \right) = \left( {I\left( {a,t} \right)P\left( {a,t} \right)\phi\left( t \right)} \right),$$where P(a,t) is the size of the population aged a at time t, and Φ(t) represents a time specific reporting rate/scaling factor.

### Likelihood and estimation {#s4-2-2}

Assuming that the observed age-specific case counts C(a,t) follow a Poisson distribution, the likelihood of the data can be expressed as$$\begin{matrix}
{L\left( C \middle| \lambda,\phi \right) = {\prod\limits_{t}{\prod\limits_{a}\frac{\left( {\Lambda\left( a,t \right)^{C(a,t)}e^{- \Lambda(a,t)}} \right)}{C\left( a,t \right)!}}},} \\
 \\
\end{matrix}$$

We fit the model in a Bayesian Markov chain Monte Carlo (MCMC) framework using the RStan package in R ([@bib37]) ([@bib40]). Both the annual hazards of infection ($\lambda$) and the reporting rates (Φ) were estimated on a logit scale using wide priors (Normal distribution with mean 0 and standard deviation of 1000). We simulated four independent chains, each of 30000 iterations and discarded the firs 10000 iterations as warm-up. We assessed convergence visually and using Rubin's R statistic. We obtained 95% credible intervals from the 2.5% and 97.5% percentiles of the posterior distributions. Code to implement the model is available at <https://github.com/isabelrodbar/dengue_foi>. ([@bib32]; copy archived at <https://github.com/elifesciences-publications/dengue_foi>).

A limitation of this approach is that, due to the large number (often in the thousands) that are characteristic of the data for some settings, the estimated confidence intervals produced are extremely narrow and do not reflect the underlying uncertainty adequately. The observed counts can also be assumed to follow a negative binomial distribution to account for some overdispersion.

### Parameters estimated {#s4-2-3}

Since it is known that the FOI has varied substantially over time in many of the settings considered, we allowed λ(t) to vary as a function of time. To limit the number of parameters estimated, we assumed constant λ(t) for periods of 20 years. Thus, if for a given setting we were estimating hazards for the period 1935--2015, we assumed piecewise-constant λ(t)s for the periods 1935--1954, 1955--1974, 1975--1994, 1995--2015. Given the objective of this study was to characterize recent transmission in endemic settings, we focused our results on the estimate of the average λ(t) for the most recent 20-year period but present other estimates in the supplementary material ([Appendix 1-Figure 1](#app1fig1){ref-type="fig"}). Rather than reporting λ(t), we focus on reporting the total FOI (4λ(t)).

### Estimating the proportion expected to be seropositive at a given age {#s4-2-4}

Using our estimates of the average FOI, we estimated the proportion of individuals expected to be seropositive by age y(x) as:$$\begin{matrix}
{y(x)} & {= 1 - x(a)} \\
 & {= 1 - e^{- 4\lambda a}} \\
\end{matrix}$$where x(a) is the proportion of the population susceptible at age a and λ is the average FOI per serotype (assuming four serotypes circulating). Since the vaccine has been registered for use in children 9 years of age or older, we report the proportion of individuals expected to be seropositive by age 9 years for each of the settings.

### Estimating the minimum age to achieve a given level of seropositivity {#s4-2-5}

Given that the WHO recommended using this vaccine in places where at least 80% of the target age group is seropositive, we estimated the minimum age at which this level of seropositivity is expected for each of the settings. For a given level of transmission λ it is possible to estimate the minimum age (A) at which a given level of seropositivity (s) is expected as:$$A\left( s \right) = \frac{- log\left( {1 - s} \right)}{4\lambda}$$

Validation and sensitivity analyses {#s4-3}
-----------------------------------

We validated our estimates of the FOI by comparing them to estimates obtained from age-stratified serological data (the gold standard) for 16 locations for which both serologic and age-specific case data was available. Methods to estimate forces of infection from seroprevalence data have been previously described ([@bib9]; [@bib30]).

Since dengue transmission is known to be highly spatially heterogeneous, we also correlated our administrative level two estimates for Colombia with known environmental drivers of dengue transmission: temperature, elevation, population density and a published composite metric of *A. aegypti* abundance ([@bib36]).

As stated above, a key assumption of this model is that the age distribution of cases represents the age distribution of secondary infections. Data from Thailand has consistently suggested that the majority of dengue hemorrhagic fever (DHF) cases arise from secondary infections ([@bib5]) and therefore we limited our analysis to reports of DHF where possible (Thailand, Brazil). However, for Colombia and Mexico we used data from severe and non severe cases because the severe dengue data alone was too sparse. To assess the impact of the data type, we compared estimates obtained from DHF/severe cases alone, to those obtained when all dengue cases were considered.

Alternative metrics {#s4-4}
-------------------

Since estimating the FOI requires fitting parametric models to the data, we explored whether alternative summary metrics, computed directly from the age-specific case data, could be equally useful in ranking spatial units within and across countries. The metrics considered included some that are commonly used by surveillance systems such as a) crude incidence and b) standardized mean incidence, but also alternative metrics that are not commonly used such as c) mean age of cases, d) cumulative proportion of incidence occurring by age 10 years and e) age at peak incidence. For each spatial unit, we computed these metrics using the most recent 5 years of data available.

Application: guiding dengue vaccination policy {#s4-5}
----------------------------------------------

The first dengue vaccine has been licensed for use in children over 9 years of age in 20 countries. Due to uncertainty regarding the vaccine's benefits and risks in individuals who haven't been previously infected by dengue, the WHO's scientific advisory group of experts (SAGE) committee recommended in April 2016 that this vaccine only be used in settings with known high endemicity, defined as places where seroprevalence is greater than 70% in the target vaccination age-group ([@bib33]), and should not be used in places where seroprevalence is under 50%.

This recommendation was later revised, and the WHO now recommends that individuals should be tested for dengue antibodies prior to vaccination, and the vaccine should only be given to individuals who have been infected by dengue in the past ([@bib43]). In the absence of appropriate serological assays that would allow for pre-vaccination screening, an alternative that has been discussed is deploying the vaccine in settings were seroprevalence is 80% or greater. These recommendations pose challenges to countries wanting to implement the vaccine, as they require detailed knowledge of the epidemiology of dengue. Specifically, they require knowledge of the population seroprevalence against dengue at subnational levels, even though such data is not available.

In order to provide information useful to countries considering deploying the vaccine according to the WHO recommendations, we used our estimates of the FOI to calculate the proportion of the population expected to be seropositive at age 9 years for of the subnational units represented in our data. We also estimated the minimum age group expected to have a seroprevalence of 80% or greater. In collaboration with the MRC center for Outbreak Analysis and Modeling, these estimates were made available online in June 2017 (<https://mrcdata.dide.ic.ac.uk/_dengue/dengue.php>) as a tool to help countries deciding where to target vaccination.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Opportunities for improved surveillance and control of infectious diseases from age-specific case data\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Jos WM van der Meer as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Eduardo Franco as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Oliver Brady (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This interesting paper provides useful insight into the challenging problem of identifying populations suitable for the deployment of the dengue vaccine, given the risk of side effects in naïve individuals upon exposure to the virus. There are however several concerns and major questions about the assumptions and their implications on the relevance of the work in terms of programmatic recommendations. Key details on the methods are lacking, so additional details are needed as they are important to ensure the correct interpretation of the findings.

Essential revisions:

1\) One of the justifications for their model is that it is better able to predict dengue infections than using recent incidence. This was used both in comparisons with the FOI in the regression analysis and also in the supplementary plots correlating ranks etc. However, \'recent incidence\' is not defined. Was this in the most recent year of data? The average over the 20-year block? Are the results sensitive to this definition? How does an age-adjusted incidence metric compare to the FOI? If a simpler approach is \'good enough\', would not this be more operationally tractable?

2\) The authors correctly assume that all 4 serotypes could be co-endemic, and that DHF cases are likely to represent the second infection, with mild cases most likely a person\'s 1st-4th infection. The focus on the issues with the current vaccination recommendations is very relevant, but it is not very clear in the text whether the authors considered \'likely seropositive\' after expected 1st infection (best candidate for vaccine) or whether it was any infection, with 2nd-4th not necessarily needing the vaccine as are already protected due to the homology between the strains. In epidemic-prone settings, this is somewhat simplified, but in areas with endemic transmission and co-circulating strains this is quite complex. If the model does in fact represent the likely first infection, then these nuances should be better described. If it regards the later infections, more justification for the relevance of the estimates should be included.

3\) To validate the estimates, the authors have plotted FOI against age-stratified serological data. However, how was case data (as labelled on the axis) estimated from FOI? Also, how were the seroprevalence estimates generated from the serological data and does this represent seropositive to all/at least 1 etc. serotypes?

4\) In addition to the limitations on the described method for calculating FOI, the paper would benefit from a few sentences in the Discussion on the limitations of using (very) long-term average FOI at a highly aggregate level to dictate control policy. Such measures will be insensitive to shorter-term changes (e.g., to interventions or a wide variety of factors that act at \< 20-year intervals) and finer-scale heterogeneities clearly occur and clearly other metrics of transmission still have a role to play in deciding dengue control policy. Suggesting that these maps might be useful for prioritising the areas where more detailed serosurveys (or individual test and vaccinate) should be done in first instance would be a more conservative interpretation than stating that vaccinating in this particular province of Brazil is \"highly questionable\".

5\) The assumptions and limitations of the described method are well detailed in the Discussion, but it would be interesting if there were any patterns in the residuals. Are there any circumstances where this method is better or worse?

6\) A major advantage of this method is international comparability, yet (as acknowledged by the authors in the Materials and methods section, but not the Results and Discussion), it is affected by different case definitions of dengue and severe dengue used in each country. Supplementary Figure 4 shows some interesting discrepancies that are not mentioned in the Results section. Thus, how generalisable are the results in countries that have much less well-defined case definitions than the countries chosen here?

7\) Regarding the methods: the use of additive force of infection (i.e. 3\*λ) seems strange and the reviewers wonder whether it quite adds up due to the multiple permutations of ways in which a person can have a secondary infection. In a multi serotype model with equal FOI between serotypes, the probability of infection with any serotype is 1-(1-λ)\^4, i.e., 1 minus probability of no infection to any serotype and slightly lower than 4\*λ. This would be worth checking as it definitely affects secondary infection attack rate.
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Author response

> Essential revisions:
>
> 1\) One of the justifications for their model is that it is better able to predict dengue infections than using recent incidence. This was used both in comparisons with the FOI in the regression analysis and also in the supplementary plots correlating ranks etc. However, \'recent incidence\' is not defined. Was this in the most recent year of data? The average over the 20-year block? Are the results sensitive to this definition? How does an age-adjusted incidence metric compare to the FOI? If a simpler approach is \'good enough\', would not this be more operationally tractable?

We apologize for the lack of clarity in terms of the metric of incidence used. Since we wanted to compare our FOI estimate to a metric of recent incidence, but acknowledging that dengue is highly variable between years, we computed the average over the last five years of available data.

We agree with the reviewers that a simpler approach would be useful and this was something that we extensively discussed with the WHO. We have compared estimates to a number of metrics, including some that are commonly used by surveillance systems such as (a) crude incidence and (b) standardized mean incidence, but also alternative metrics that are not as commonly used such as (c) mean age of cases, (d) cumulative proportion of incidence occurring by age 10 years (Cum10) and (e) age at peak incidence. We computed these metrics for each spatial unit using the most recent 5 years of data available.

As shown in Figure 1---figure supplement 1, the incidence metrics perform very poorly in ranking spatial units compared to the FOI. In contrast, Cum10 and the mean age of cases (to a lesser degree), perform quite well at ranking spatial units within countries. However, none of the metrics performs as well as the FOI when comparing countries, and they do not correlate as well with the gold standard (FOI estimates derived from seroprevalence data) as shown in Figure 1---figure supplement 2.

We have included sections in the manuscript (Materials and methods, subsection "Alternative metrics" and Results subsection, "Alternative metrics") where we describe these results evaluating the performance of alternative metrics.

> 2\) The authors correctly assume that all 4 serotypes could be co-endemic, and that DHF cases are likely to represent the second infection, with mild cases most likely a person\'s 1st-4th infection. The focus on the issues with the current vaccination recommendations is very relevant, but it is not very clear in the text whether the authors considered \'likely seropositive\' after expected 1st infection (best candidate for vaccine) or whether it was any infection, with 2nd-4th not necessarily needing the vaccine as are already protected due to the homology between the strains. In epidemic-prone settings, this is somewhat simplified, but in areas with endemic transmission and co-circulating strains this is quite complex. If the model does in fact represent the likely first infection, then these nuances should be better described. If it regards the later infections, more justification for the relevance of the estimates should be included.

We agree with the reviewer that individuals who have experienced only the first dengue infection are probably the best candidates for vaccination. However, both of the SAGE recommendations (from 2016 and 2018) are based on overall seropositivity (to one or more serotypes) and do not consider the number of infections an individual may have experienced. Since one of our objectives was to generate estimates that could help countries implement the vaccine based on the WHO recommendation, we chose to focus on this metric and we used our estimates of the force of infection to calculate the expected proportion of seropositive individuals (to one or more serotypes). It would also be possible to reconstruct the expected proportion of individuals that have been infected by a single serotype, but we believe it is outside of the scope of this paper (and can't be measured with standard serological assays).

> 3\) To validate the estimates, the authors have plotted FOI against age-stratified serological data. However, how was case data (as labelled on the axis) estimated from FOI? Also, how were the seroprevalence estimates generated from the serological data and does this represent seropositive to all/at least 1 etc. serotypes?

We apologize for the confusion. The plot in Figure 1 shows estimates of FOI derived from case data vs estimates of FOI derived from age-stratified seroprevalence data (the gold standard). These estimates of the FOI were generated by fitting catalytic models to age-specific seroprevalence data as previously described by us and others (Ferguson et al., 1999; Rodriguez-Barraquer et al., 2011), and they represent being seroposive to at least 1 serotype.

We have updated the figure label (Figure 1C) and edited the Materials and methods subsection "Validation and sensitivity analyses" as follows:

"We validated our estimates of the force of infection by comparing them to estimates obtained from age-stratified serological data (the gold-standard) for 16 locations for which both serologic and age-specific case data was available. Methods to estimate forces of infection from seroprevalence data have been previously described".

> 4\) In addition to the limitations on the described method for calculating FOI, the paper would benefit from a few sentences in the Discussion on the limitations of using (very) long-term average FOI at a highly aggregate level to dictate control policy. Such measures will be insensitive to shorter-term changes (e.g., to interventions or a wide variety of factors that act at \< 20-year intervals) and finer-scale heterogeneities clearly occur and clearly other metrics of transmission still have a role to play in deciding dengue control policy. Suggesting that these maps might be useful for prioritising the areas where more detailed serosurveys (or individual test and vaccinate) should be done in first instance would be a more conservative interpretation than stating that vaccinating in this particular province of Brazil is \"highly questionable\".

We chose to estimate average forces of infection over a 20 year period because we were interested in capturing average transmission risk for each location, rather than estimating forces of infection for specific years. We believe that these longer-term averages better reflect the transmission potential within a location and are less susceptible to transient events. However, we agree with the reviewers that averages over 20 years and over large spatial units likely conceal heterogeneities in FOI that exist at finer spatio-temporal scales.

Rather than replacing seroprevalence surveys, which are still the gold-standard, we hope that our approach and results will serve as an additional tool to help guide interventions when seroprevalence surveys are not available.

We have expanded the Discussion to incorporate both of these ideas.

"While age-stratified serological data remains the gold-standard to quantify dengue transmission, our results illustrate how inferences derived from age-specific surveillance data could be used to inform control interventions such as vaccination. \[...\] While here we focus on presenting average forces of infection over 20 years, the same methods can also be used to estimate yearly forces of infection (Cummings et al., 2009; Hoang Quoc et al., 2016)."

"Our model also makes several assumptions that may be questionable. \[...\] Finally, it estimates transmission intensities over extended periods of time (20 years), averaging over variations in the FOI that may occur at shorter time scales."

> 5\) The assumptions and limitations of the described method are well detailed in the Discussion, but it would be interesting if there were any patterns in the residuals. Are there any circumstances where this method is better or worse?

The main assumption of our model is that the age distribution of reported cases represents the age distribution of secondary infections. Thus, the main threats to model performance are biases in the reporting process that invalidate this assumption.

While it is well established that the main risk factor for dengue hemorrhagic fever is having a secondary dengue infection, it is possible that other infections (primary, tertiary or quaternary) might contribute to milder forms of the disease. Thus, the model can be expected to perform better when fit to age-specific DHF data. Using data from milder forms of dengue could further threaten model performance because "dengue fever" is a non-specific clinical diagnosis and therefore more likely to be misclassified.

As described in response to comment 6, to assess the potential impact of reporting biases we have compared FOI estimates derived from severe/DHF cases to those derived from all cases combined. These results have now been included in the manuscript.

We do not think that the residuals are a good metric of model performance because near-perfect fits do not imply unbiased estimates of the FOI. Rather than looking at the residuals, proper assessment of model performance would require comparing estimates to validation data (age-stratified serological data) from more locations.

> 6\) A major advantage of this method is international comparability, yet (as acknowledged by the authors in the Materials and methods section, but not the Results and Discussion), it is affected by different case definitions of dengue and severe dengue used in each country. Supplementary Figure 4 shows some interesting discrepancies that are not mentioned in the Results section. Thus, how generalisable are the results in countries that have much less well-defined case definitions than the countries chosen here?

We thank the reviewer for their comment. Differences in reporting practices could certainly impact the comparability of estimates between countries. A key assumption of our model is that the age distribution of reported cases represents the age distribution of secondary infections. While it is well established that the main risk factor for dengue hemorrhagic fever is having a secondary infection, it is possible that other infections (primary, tertiary or quaternary) contribute to milder forms of the disease. Furthermore, the case definition of severe dengue and DHF is more specific, while milder forms of dengue are more likely to be misclassified.

Where possible (Thailand and Brazil) we used age-specific case reports on dengue hemorrhagic fever for our analyses. However, for both Colombia and Mexico we had to use data on all reported dengue cases because the DHF data was too sparse and a substantial number of spatial units (9/32 in Colombia and 10/31 in Mexico) didn't include enough cases to estimate the FOI.

To assess the sensitivity of our estimates to the report type, we have compared FOI estimates derived from severe/DHF cases to those derived from all cases combined. This comparison was limited to Colombia, Brazil and Mexico because from Thailand we only had DHF data (Figure 4A). For most settings, the correlation between the estimates was good. This was particularly true for Colombia and Mexico, but less so for Brazil. However, two-thirds of the Brazilian locations that showed discrepant results had the smallest number of DHF cases (n=217 and 265) suggesting that sample size may have played a role. Similarly, all of the Colombian locations where there was a large discrepancy had very low counts of DHF cases (n= 41, 55, and 48 respectively). The state of Maranhao in Brazil showed a large discrepancy despite having large numbers of cases, due to major differences in the age distribution of severe vs. mild infections. In general, estimates derived from DHF cases tended to be slightly greater than those from all cases. However, both types of estimates correlated well with the gold standard (Figure 4B).

We think that these results are encouraging, and suggests that even data from all dengue cases can be useful to infer transmission patterns. However, it is possible that for countries that have less well-defined case definitions, it might be better to use models that make different assumptions about the observation process. For example, it may be necessary to relax the assumption that cases represent secondary infections and allow for mixtures between primary, secondary and post-secondary infections.

We have added a section on the sensitivity analyses comparing different report types (Results, subsection "Sensitivity analyses") and added the following paragraph to the Discussion:

"There are several limitations of using age-specific surveillance data to estimate transmission parameters of dengue. \[...\] Nevertheless, our results and sensitivity analyses are encouraging and suggest that even data from all dengue cases can be useful to infer transmission patterns."

> 7\) Regarding the methods: the use of additive force of infection (i.e. 3\*λ) seems strange and the reviewers wonder whether it quite adds up due to the multiple permutations of ways in which a person can have a secondary infection. In a multi serotype model with equal FOI between serotypes, the probability of infection with any serotype is 1-(1-λ)\^4, i.e., 1 minus probability of no infection to any serotype and slightly lower than 4\*λ. This would be worth checking as it definitely affects secondary infection attack rate.

We are a bit confused by the reviewer's comment. In our model formulation the λ is a rate (not a probability). Thus, 4\*λ represents the annual rate at which susceptibles get infected by any of the four serotypes, and the annual probability of infection is 1- exp(-4\*λ). Similarly, 3\*λ represents the rate at which susceptibles get infected by any of 3 serotypes.

We express the expected rate of secondary infections as $I(a,t) = 3\lambda(t)z_{1}(a,t)$. This represents the product of the rate of infection by 3 serotypes (because the person is already immune to the fourth one) and the probability that the person is susceptible to secondary infections. A similar approach has been previously used (Salje et al., 2019; Imai et al., 2016). The reviewer is right in pointing out that when calculating the number of secondary infections over a full year, 3\*λ may slightly overestimate 1- exp(-3\*λ). However, as shown in [Author response image 1](#respfig1){ref-type="fig"}, this alternative formulation has no impact on our estimates of the of the force of infection.
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